116 related articles for article (PubMed ID: 35787343)
1. Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China.
Gao H; Liu Y; Xu Y; Mi L; Zhang C; Wang X; Song Y; Zhu J; Liu W
J Formos Med Assoc; 2022 Dec; 121(12):2556-2565. PubMed ID: 35787343
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and cardiac toxicity of different-dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma.
Li L; Chen R; Zhou D; Sun J; Wang L; Zhu L; Shen H; Xie W; Ye X
Cancer Med; 2023 Feb; 12(4):4184-4194. PubMed ID: 36200320
[TBL] [Abstract][Full Text] [Related]
3. Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimoyama T
Ann Hematol; 2023 Jun; 102(6):1485-1500. PubMed ID: 37115298
[TBL] [Abstract][Full Text] [Related]
4. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
5. An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study.
Hiroi T; Hosoi H; Kuriyama K; Murata S; Morimoto M; Mushino T; Nishikawa A; Tamura S; Sonoki T
J Geriatr Oncol; 2023 Jan; 14(1):101396. PubMed ID: 36328877
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
[TBL] [Abstract][Full Text] [Related]
8. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
[TBL] [Abstract][Full Text] [Related]
9. Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Yamamoto M; Suzuki I; Saitou K; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Satoh S; Tajima K
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2995-3002. PubMed ID: 32524293
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma.
Zhou X; Wang Y; Li X
Pak J Pharm Sci; 2021 Nov; 34(6(Special)):2455-2459. PubMed ID: 35039259
[TBL] [Abstract][Full Text] [Related]
11. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
12. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
[TBL] [Abstract][Full Text] [Related]
13. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields P; Gunawan A; Oliver R; Djebbari F; Booth S; McMillan A; Fox CP; Bishton MJ; Collins GP; Hatton CSR
J Intern Med; 2019 Jun; 285(6):681-692. PubMed ID: 30811713
[TBL] [Abstract][Full Text] [Related]
14. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma.
Utsu Y; Takaishi K; Inagaki S; Arai H; Yuasa H; Masuda S; Matsuura Y; Aotsuka N; Wakita H
Ann Hematol; 2016 Jan; 95(1):41-47. PubMed ID: 26435364
[TBL] [Abstract][Full Text] [Related]
15. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
16. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
17. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
18. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma.
Terada Y; Nakamae H; Aimoto R; Kanashima H; Sakamoto E; Aimoto M; Inoue E; Koh H; Nakane T; Takeoka Y; Ohsawa M; Koh KR; Yamane T; Nakao Y; Ohta K; Mugitani A; Teshima H; Hino M
J Exp Clin Cancer Res; 2009 Aug; 28(1):116. PubMed ID: 19689822
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis.
Oiwa K; Fujita K; Lee S; Morishita T; Tsukasaki H; Negoro E; Hara T; Tsurumi H; Ueda T; Yamauchi T
ESMO Open; 2021 Aug; 6(4):100210. PubMed ID: 34271313
[TBL] [Abstract][Full Text] [Related]
20. Association between Comorbidity and Relative Dose Intensity in Patients with Diffuse Large B-Cell Lymphoma.
Yamamoto M; Suzuki I; Yokoyama M
Gan To Kagaku Ryoho; 2019 Dec; 46(12):1855-1859. PubMed ID: 31879403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
